GlobalSpace Technologies launched exclusive digital ​platform

IMT News Desk
IMT News Desk
· 2 min read
Krishna Singh, Founder, Chairman & Managing Director, GlobalSpace Technologies

GlobalSpace Technologies launched DocExa, “an exclusive digital ​platform developed using AI technology to help Doctors efficiently manage their patients & other engagements”, during DigiPharmaX (Digital Pharma Excellence) Awards 2017 at Mumbai. DocExa leverages artificial intelligence, cloud & mobility technology to empower Doctor, Patients & Pharma companies for meaningful & transparent engagement.

DocExa helps create a transparent engagement between the Doctor and Pharmaceutical communities, while adhering to the Government regulations and guidelines like UCPMP. Additionally, doctors can file ADR through DocExa which provides real-time access of adverse drug reactions reports to Pharmaceutical companies and helps them to improve the quality of drugs. Doctors can also avail medico-legal consulting from a team of trusted, verified and reputed Legal Advisors, with the help of just a click or a tap.

Today 60% of India’s population lies in tier two or three states. With greater penetration of mobility and growing number of internet users in rural India, pharmaceutical companies will be able to expand their reach to connect with increasing number of doctors through the DocExa platform. Leveraging technology, Doctors based in rural areas will be able to stay updated with the latest medical advancements and drug brands in the market, creating a win-win for the entire industry.

Speaking on the launch, Krishna Singh, Founder, Chairman & Managing Director, GlobalSpace Technologies said, “DocExa is the industry’s first AI driven Doctor-Pharmaceutical-Patient Connect Platform. In India, still the Doctor- Patient ratio is abysmally low at 1:1700. In its evolved form Docexa can enable Doctors to carry out differential diagnostics & help more number of patients, efficiently.

He further added, “DocExa is a step forward towards digital India and by digitally connecting the critical  stakeholders of healthcare ecosystem, irrespective of their location, can access the most advanced health care services through technology. With the help of DocExa, we plan to connect over half a million doctors & 10 million patients by 2019.”

Built on latest AI algorithms, the app is cross-platform and can be accessed through a smartphone or a tab at any time and pace.

Read Next

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care
News
July 17, 2026

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care

Menthra, an AI-powered emotional wellbeing platform, today announced the launch of Menthra Care in India, expanding its platform to connect users with verified therapists, coaches, licensed clinical professionals and care organisations when they need support beyond an AI companion. The launch follows Menthra’s India debut in June, which saw tens of thousands of users join […]
Article by: IMT News Desk
IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care
News
July 17, 2026

IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care

Against a backdrop of geopolitical uncertainty, supply chain disruptions and rapid advances in artificial intelligence (AI) and precision medicine, FutureHealth.Now provided a platform for industry leaders to explore how innovation, technology and new models of care can help tackle rising healthcare costs, workforce pressures and growing demand for services across the region. At his opening […]
Article by: IMT News Desk
Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill
News
July 16, 2026

Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill

Novo Nordisk has secured European Commission approval for its once-daily Wegovy pill, giving the Danish drugmaker a major boost in the fast-growing obesity-treatment market. The approval makes it the first oral GLP-1 weight-loss treatment cleared in the European Union for adults with obesity or overweight who also have at least one weight-related health condition. The […]
Article by: IMT News Desk
Sun Pharma Wins South Africa Approval to Launch Generic Ozempic
News
July 16, 2026

Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

India’s Sun Pharmaceutical Industries has received approval from South Africa’s health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, expanding its presence in the fast-growing GLP-1 market. The South African Health Products Regulatory Authority’s clearance allows Sun Pharma to market the injectable treatment for […]
Article by: IMT News Desk